MYC inhibitor DC-34 is primarily used in cancer research and treatment due to its ability to target and inhibit the MYC oncoprotein. MYC is a critical regulator of cell growth and proliferation, and its overexpression is commonly associated with various cancers. By inhibiting MYC, DC-34 can potentially suppress tumor growth and progression. This makes it a valuable tool in preclinical studies aimed at understanding MYC-driven cancers and developing targeted therapies. Additionally, DC-34 is being explored for its potential to enhance the efficacy of existing cancer treatments when used in combination with other chemotherapeutic agents. Its application extends to studying the molecular mechanisms of MYC in cellular processes, providing insights into novel therapeutic strategies for cancer.